Akebia Therapeutics, Inc. (NASDAQ:AKBA) SVP Michel Dahan sold 1,398 shares of the business’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $19.64, for a total value of $27,456.72. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Michel Dahan also recently made the following trade(s):

  • On Thursday, September 28th, Michel Dahan sold 5,000 shares of Akebia Therapeutics stock. The stock was sold at an average price of $19.30, for a total value of $96,500.00.
  • On Tuesday, August 15th, Michel Dahan sold 5,000 shares of Akebia Therapeutics stock. The stock was sold at an average price of $15.00, for a total value of $75,000.00.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) remained flat at $19.23 on Thursday. The company had a trading volume of 315,281 shares. The stock’s market capitalization is $351.91 million. Akebia Therapeutics, Inc. has a 12-month low of $7.16 and a 12-month high of $20.25. The firm’s 50 day moving average price is $17.09 and its 200 day moving average price is $13.79.

Akebia Therapeutics (NASDAQ:AKBA) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.89) by $0.36. The firm had revenue of $28.52 million during the quarter, compared to analysts’ expectations of $26.50 million. Equities analysts predict that Akebia Therapeutics, Inc. will post ($2.57) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Akebia Therapeutics, Inc. (AKBA) SVP Michel Dahan Sells 1,398 Shares of Stock” was originally published by Marea Informative and is the property of of Marea Informative. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at http://www.mareainformativa.com/akebia-therapeutics-inc-akba-svp-michel-dahan-sells-1398-shares-of-stock/117807/.

A number of large investors have recently added to or reduced their stakes in AKBA. Teachers Advisors LLC increased its position in Akebia Therapeutics by 4.0% in the fourth quarter. Teachers Advisors LLC now owns 63,804 shares of the biopharmaceutical company’s stock worth $664,000 after buying an additional 2,454 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of Akebia Therapeutics by 734.2% in the first quarter. Russell Investments Group Ltd. now owns 89,467 shares of the biopharmaceutical company’s stock worth $823,000 after acquiring an additional 78,742 shares during the period. American International Group Inc. boosted its holdings in shares of Akebia Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 22,121 shares of the biopharmaceutical company’s stock worth $204,000 after acquiring an additional 1,460 shares during the period. Wellington Management Group LLP boosted its holdings in shares of Akebia Therapeutics by 17.4% in the first quarter. Wellington Management Group LLP now owns 152,020 shares of the biopharmaceutical company’s stock worth $1,399,000 after acquiring an additional 22,520 shares during the period. Finally, MARSHALL WACE ASIA Ltd bought a new position in shares of Akebia Therapeutics in the first quarter worth $6,232,000. 57.62% of the stock is owned by institutional investors and hedge funds.

A number of research firms recently weighed in on AKBA. Mizuho began coverage on Akebia Therapeutics in a report on Wednesday. They set a “buy” rating and a $24.00 target price on the stock. Royal Bank Of Canada reissued an “outperform” rating and set a $28.00 target price on shares of Akebia Therapeutics in a report on Saturday, September 16th. ValuEngine raised Akebia Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, September 1st. BidaskClub raised Akebia Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, August 16th. Finally, Zacks Investment Research raised Akebia Therapeutics from a “hold” rating to a “buy” rating and set a $16.00 target price on the stock in a report on Monday, August 14th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Akebia Therapeutics presently has an average rating of “Buy” and an average target price of $22.00.

About Akebia Therapeutics

Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).

Insider Buying and Selling by Quarter for Akebia Therapeutics (NASDAQ:AKBA)

Receive News & Stock Ratings for Akebia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics Inc. and related stocks with our FREE daily email newsletter.